Key facts
- Mainland Chinese investment funds are increasing their stakes in Hong Kong-listed biotechnology companies.
- This investment activity is happening concurrently with a surge in licensing deals within the biotech sector.
Mainland Chinese investment funds have been increasing their stakes in Hong Kong-listed biotechnology companies. This trend is occurring alongside a notable surge in licensing deals within the biotech sector, indicating a period of heightened activity and investor interest in the region's life sciences industry.